William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on SPRY stock, giving a Buy rating on November 4.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors that highlight the promising outlook for ARS Pharmaceuticals. The recent data presented at the ACAAI 2025 annual meeting demonstrated that neffy, ARS’s product, is an effective alternative to injectable epinephrine, showing comparable clinical efficacy and ease of use. This data is expected to build confidence among healthcare professionals who may have been hesitant to adopt neffy without real-world effectiveness data.
Furthermore, ARS Pharmaceuticals is actively working to overcome access barriers, which have been a significant challenge for broader adoption. The introduction of the ‘Get neffy on Us’ program aims to alleviate the burden of in-office visits and prior authorizations, potentially increasing neffy’s adoption in the coming quarters. Additionally, the tolerability profile of neffy appears more favorable compared to competitors, further supporting its potential for increased market penetration.
Hanbury Brown covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, Ocular Therapeutix, and Harrow Health. According to TipRanks, Hanbury Brown has an average return of 13.6% and a 57.89% success rate on recommended stocks.
In another report released on November 4, Roth MKM also initiated coverage with a Buy rating on the stock with a $30.00 price target.